Crossmark

Safety and efficacy of teriflunomide on clinical course, and laboratory findings in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis: a triple-blind study

Crossref DOI link: https://doi.org/10.1007/s00415-025-13134-9

Published Online: 2025-05-10

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jozan, Neda Ghadiri

Vahidi, Zohreh

Rafatpanah, Houshang

Boostani, Reza

Zemorshidi, Fariba

Sahraian, Mohammadali

Tabeshpour, Jamshid

Baghaei, Mahdieh

Nahayati, Mohammadali https://orcid.org/0000-0001-8373-6053
License Information

Text and Data Mining valid from 2025-05-10

Version of Record valid from 2025-05-10
More Information

Article History

Received: 11 December 2024

Revised: 28 April 2025

Accepted: 1 May 2025

First Online: 10 May 2025

Change Date: 5 July 2025

Change Type: Update

Change Details: ORCiD number for Mohammadali Nahayati was incorrect and should be 0000-0001-8373-6053

Declarations

: Conflicts of interestMohammadali Nahayati: has received educational and research grants, lecture honoraria, and travel supports to attend scientific meetings from Cinnagen, Zistdaru, Abidi, Merck-Sereno, Novartis, Nano alvand and Biogen-Idec. Mohammadali Sahraian: has received educational and research grants, lecture honoraria, and travel supports to attend scientific meetings from Abidi, Biogen-Idec, Merck-Serono, Bayer-Schering- Novartis, Cinnagen, Osveh, Zistdaru, Zahravi and Genzyme.

: Approval for the study protocol was obtained from the Ethics Committee of Mashhad University of Medical Sciences (IR.MUMS.MEDICAL.REC.1399.441). Written informed consent was obtained and recorded in their medical records.

: Not applicable.

Document is current

Any future updates will be listed below